PROGRAMMA.ANN.MEET.2017.rev.del 12_Feb.2017

Transcript

AISF
ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO
Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell’Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011
50th AISF Annual Meeting
rd
th
Rome, February 23 -24 , 2017
SCIENTIFIC PROGRAMME
Thursday, February 23rd
08.30-10.00 Selected Oral Communications
(NAFLD/ALD clinical and experimental)
Chairpersons: A.L. Fracanzani, Milan
F. Nascimbeni, Modena
08.30-08.45 Increased hepatic glucose production and
insulin resistance are associated to
increased plasma concentrations of
glucogenic amino acids in subjects with
NAFLD
M. Gaggini, C. Rosso, F. Carli, V. Della Latta,
D. Ciociaro, M. Marietti, E. Buzzigoli,
M.L. Abate, R. Gambino, M. Cassader,
A. Smedile, E. Bugianesi, A. Gastaldelli - Pisa,
Turin
08.45-09.00 The hepatic expression of lysosomal acid
lipase (LAL) is reduced in NAFLD patients,
and associated with features of geneticallydetermined LAL deficiency and NAFLD
activity score
U. Vespasiani-Gentilucci, F. Valentini,
S. Carotti, F. Vorini, M. Zingariello,
M. Francesconi, G. Galati, P. Gallo,
A. De Vincentis, C. Dell’Unto, S. Morini,
A. Picardi - Rome
09.00-09.15 Serial combination of noninvasive tools
improves the diagnostic accuracy of severe
liver fibrosis in patients with nonalcoholic
fatty liver disease
S. Petta, V.W-S. Wong, C. Cammà,
J-B. Hiriart, G.L-H. Wong, J. Vergniol,
A.W-H. Chan, V. Di Marco, W. Merrouche,
H.L-Y. Chan, F. Marra, B. Le-Bail, U. Arena,
A. Craxì, V. de Ledinghen - Palermo, Hong
Kong, Pessac (France), Florence, Bordeaux
(France)
09.15-09.30 The combination of mucus-degrading gramnegative bacteria and reduced antimicrobial
peptides drives adipose tissue inflammation
and NAFLD progression in mice lacking
NLRP3-inflammasome
I. Pierantonelli, C. Rychlicki, D. Giordano,
A. Giordano, S. Uzzau, A. Gastaldelli,
L. Sartini, L. Trozzi, A. Benedetti,
M. Marzioni, S. Cinti, G. Svegliati-Baroni
Ancona, Alghero (SS), Sassari, Pisa
09.30-09.45 Steatohepatitis and type 2 diabetes mellitus
are influenced by genetic susceptibility to
increased intestinal permeability in patients
with non-alcoholic fatty liver disease
V. Giorgio, L. Miele, S. Petta, A. Liguori,
R. Pastorino, G. Marrone, M. Biolato,
C. Araneo, F.G. Vaccaro, C. Cefalo, D. Arzani,
G.L. Rapaccini, A. Gasbarrini, S. Boccia,
A. Craxì, A. Grieco - Rome, Palermo
09.45-10.00 Down-regulation of hepatic MBOAT7 by
hyperinsulinemia
favors
steatosis
development
M. Meroni, P. Dongiovanni, R. Rametta,
G.A. Bassani, S. Badiali, S. Romeo, S. Gatti,
L. Valenti - Milan, Gothenburg (Sweden)
10.00-10.30 State-of-the-Art Lecture
Introduced by: A. Gasbarrini, Rome
How to translate research into policy
change: the case of HCV
M. Melazzini, Rome
10.30-11.00 Coffee break and Posters view
Tutors: L. Maroni, Ancona
F. Salomone, Catania
11.00-12.15 General Assembly II
(Hepatocellular carcinoma clinical and
experimental)
Chairpersons: G. Cabibbo, Palermo
F. Farinati, Padua
12.15-12.30 External validation of the ITA.LI.CA
prognostic system for patients with
hepatocellular carcinoma: a multicenter
cohort study
E. Dionigi, M. Borzio, A. Rossini,
M. Marignani, R. Sacco, I. De Sio, E. Bertolini,
G. Francica, A. Giacomin, G. Parisi, S. Vicari,
A. Toldi, A. Salmi, S. Boccia, A. Maringhini,
F. Fornari - Melegnano (MI), Brescia, Rome,
Pisa, Naples, Castelvolturno (CE), Padua,
Feltre (BL), Bologna, Como, Verona, Ferrara,
Palermo, Piacenza
AISF
12.30-12.45 The concept of therapeutic hierarchy for
patients with hepatocellular carcinoma: a
multicentre cohort study
A. Vitale, F. Farinati, T.L. Huo, F. Trevisani,
E.G. Giannini, F. Piscaglia, U. Cillo - Padua,
Taipei (Taiwan), Bologna, Genoa
12.45-13.00 Oncostatin
M
induces
increased
invasiveness and angiogenesis in hepatic
cancer cells through HIF1α-related release
of VEGF-A
B. Foglia, S. Cannito, E. Morello, C. Turato,
G. Di Maira, E. Novo, S. Colombatto,
P. Pontisso, F. Marra, M. Parola - Turin,
Padua, Florence
13.00-13.15 Impact of natural killer (NK) cells receptors
gene haplotypes on the development of
hepatocarcinoma in cirrhotic patients
S. Onali, R. Littera, M. Casale, F. Capraro,
C. Balestrieri, F. Figorilli, G. Serra,
E. Congeddu, P. Ragatzu, R. Maddi, M. Serra,
V. Loi, M. Trucas, C. Carcassi, L. Chessa
Cagliari
13.15-13.45 Young Investigator Lecture
Introduced by:
G. Marchesini Reggiani, Bologna
Hepatitis C virus and metabolism
S. Petta, Palermo
13.45-14.45 Lunch break and Posters view
Tutors: R. D’Ambrosio, Milan
C. Rosso, Turin
14.45-15.30 2015 AISF Fellowships Report
Introduced by: M. Marzioni, Ancona
14.45-15.00 Generation of an in vitro model of Primary
Sclerosing Cholangitis
D. Costantini, Rome
15.00-15.15 The Klotho-beta (KLB) variant rs17618244
influences circulating levels of KLB and
severity of disease in paediatric patients with
NAFLD
A. Crudele, Rome
15.15-15.30 Ischemia/Reperfusion damage modulation in
steatotic liver through Adenosine receptors
stimulation
C. Imarisio, Novara
Introduced by: E.G. Giannini, Genoa
The changing epidemiology of liver diseases
in Europe
M. Peck-Radosavljevic, Klagenfurt-Austria
16.00-16.15 Presentation of the AISF prize for the 2 best
Italian papers in 2015
Introduced by: C. Cammà, Palermo
Basic science
Natural killer cell phenotype modulation
and natural killer/T-cell interplay in
nucleos(t)ide analogue-treated hepatitis e
antigen-negative patients with chronic
hepatitis B
Hepatology 2015. Dec;62(6):1697-709
C. Boni, P. Lampertico, L. Talamona,
T. Giuberti, F. Invernizzi, V. Barili, P. Fisicaro,
M. Rossi, M.C. Cavallo, A. Vecchi, G. Pedrazzi,
A. Alfieri, M. Colombo, G. Missale, C. Ferrari
Parma, Milan
Clinical
Prognosis of untreated hepatocellular
carcinoma
Hepatology 2015. Jan;61(1):184-90
E.G. Giannini, F. Farinati, F. Ciccarese,
A. Pecorelli, G.L. Rapaccini, M. Di Marco,
L. Benvegnù, E. Caturelli, M. Zoli, F. Borzio,
M. Chiaramonte, F. Trevisani
Italian Liver Cancer (ITA.LI.CA) group
C. Rosso, Turin
(Hepatitis C, B and delta clinical)
Chairpersons: A. Aghemo, Milan
U. Vespasiani-Gentilucci, Rome
16.45-17.00 Efficacy of oral direct acting antivirals for
treatment of advanced chronic hepatitis or
compensated cirrhosis due to Hepatitis C
virus infection: the real-life experience of
the Sicily registry
I. Cacciola, S. Petta, M. Distefano,
M.R. Cannavò, A. Davì, S. Madonia,
V. Calvaruso, L. Larocca, F. Di Lorenzo,
A. Digiacomo, G. Bertino, A. Licata, F. Latteri,
F. Benanti, R. Volpes, L. Guarneri,
A. Averna, I. Scalisi, C. Iacobello, P. Colletti,
F. Cartabellotta, V. Portelli, M. Russello,
G. Scifo, G. Squadrito, G. Raimondo, A. Craxì,
V. Di Marco on behalf of RESIST-HCV (Rete
Sicilia Selezione Terapia - HCV)
17.00-17.15 Role of SerpinB3 in the stimulation of
macrophage activation marker sCD163 in
HCV infected patients
A. Martini, A. Cappon, A.Biasiolo, C. Turato,
P. Pontisso - Padua
AISF
17.15-17.30 Peripheral and intrahepatic virological
phenotyping in HBeAg negative Chronic
Hepatitis B to evaluate risk of disease
progression and HCC in the “grey-zone” viral
load cohort: can grey-zone patients be
candidate to treatment?
R. Salpini, L. Colagrossi, A. Battisti, N. Hansi,
C.F. Perno, U.S. Gill, P.T.F. Kennedy,
V. Svicher - Rome, London (UK)
17.30-17.45 The challenge of HCV-retreatment after
DAA-failure: Italian real-life from VIRONET-C
network
V. Cento, S. Barbaliscia, V.C. Di Maio,
C. Masetti, C. Minichini, C.F. Magni,
V. Micheli, S. Marenco, L.A. Nicolini,
B. Bruzzone, Y. Troshina, C. Baiguera,
C. Dentone, V. Calvaruso, S. Paolucci,
M. Melis, M. Aragri, A. Bertoli, I. Lenci,
S. Landonio, M. Schiavini, L. Sticchi,
T. Ruggiero, E. Polilli, V. Messina, A. Pellicelli,
L. Boglione, R. Cozzolongo, M. Biolato,
F. Morisco, M. Siciliano, G. Parruti,
G. Barbarini, A. Craxì, S. Babudieri, M. Puoti,
A. Ciancio, G. Rizzardini, N. Coppola,
M. Angelico, C.F. Perno, F. CeccheriniSilberstein on behalf of VIRONET-C - Rome,
Naples, Milan, Genoa, Turin, Sanremo (IM),
Palermo, Pavia, Sassari, Pescara, Caserta,
Castellana Grotte (BA), Pavia
17.45-18.00 High rates of renal tubular damage in HBV
monoinfected patients long-term treated
with Tenofovir: a cross-sectional, single
center, real-life study in 414 patients
G. Grossi, A. Loglio, F. Facchetti, E. Galmozzi,
M. Colombo, P. Lampertico - Milan, Rozzano
(MI)
18.00-18.15 Prothrombotic microparticles and risk of
portal vein thrombosis in patients with
HCV-related liver cirrhosis who underwent
DAA antiviral therapy
A. Zanetto, E. Campello, C.M. Radu,
S. Shalaby, E. Franceschet, A.M. Frigo,
A. Ferrarese, I. Bortoluzzi, M. Gambato,
G. Germani, M. Senzolo, A. Floreani,
F. Farinati, P. Burra, P. Simioni, F.P. Russo
Padua
18.15-18.30 Abnormal microvasculature in chronic viral
hepatitis
S. Sarcognato, F. Farinati, R. Cardin,
F.P. Russo, M. Piciocchi, V. Guzzardo,
L. Giacomelli, M. Guido - Padua
Friday, February 24th
(Liver failure, hepatobiliary surgery, and
transplantation)
Chairpersons: A. Cucchetti, Bologna
P. Toniutto, Udine
08.30-08.45 External validation of the HCC-MELD score
for patients with hepatocellular carcinoma
waiting for liver transplantation
A. Vitale, A.C. Frigo, P. Burra, P. Angeli,
G. Zanus, U. Cillo - Padua
08.45-09.00 Entecavir or Tenofovir monotherapy
prevents HBV recurrence in liver transplant
recipients: a 5-year follow-up study after
Hepatitis B immunoglobulin withdrawal
M.A. Manini, M. Bruce, I. Carey,
G. Whitehouse, B. Wang, E. Gonsalkorala,
A. Considine, P. Lampertico, K. Agarwal
London (UK), Milan
09.00-09.15 A new strategy to improve the liver
engraftment efficiency of transplanted
human biliary tree stem/progenitor cells
(hBTSCs): cell coating with hyaluronic acid
L. Nevi, G. Carpino, D. Costantini,
V. Cardinale, O. Riccioni, S. Di Matteo,
F. Melandro, P.B. Berloco, L. Reid, E. Gaudio,
D. Alvaro - Rome, Chapel Hill (USA)
09.15-09.30 Parenchymal sparing vs. anatomic resection
for HCC: a propensity score analysis
S. Famularo, A. Giani, S. Di Sandro,
M. Sandini, A. Giacomoni, E. Pinotti,
L. Nespoli, L. Gianotti, L. De Carlis, F. Romano
Milan, Monza (MB)
09.30-09.45 The survival benefit of laparoscopic ablation
over trans-arterial chemoembolization in
patients with hepatocellular carcinoma
ineligible for liver resection or percutaneous
ablation
A. Bertacco, A. Marchini, A. Vitale,
C. Ungaro, F. D'Amico, E. Gringeri, D. Neri,
D. Bassi, G. Zanus, R. Carandina, C. Aliberti,
U. Cillo Padua
AISF
09.45-10.00 Outcome of liver transplant recipients after
the first episode of bacterial infection
A. Ferrarese, A. Zanetto, G. Germani,
M. Gambato, F.P. Russo, U. Cillo, P. Angeli,
P. Burra, M. Senzolo - Padua
Introduced by: A. Craxì, Palermo
Eradication, elimination or disease control
of HCV infection
A. Alberti, Padua
Tutors: L. Maroni, Ancona
11.00-12.20 Symposium "A systems medicine approach
to liver diseases"
Chairpersons: D. Alvaro, Rome
F. Bonino, Pisa
11.00-11.20 Large-scale computational models of liver
metabolism: how far from the clinics?
D. Rozman, Ljubljana-Slovenia
11.20-11.40 The role of genomics and biomarkers as a
guide to diagnosis and therapeutic choices
for patients with rare liver diseases
P. Invernizzi, Milan
11.40-12.00 How the use of large clinical databases may
improve the management of patients with
liver cancer - F. Trevisani, Bologna
12.00-12.20 Discussion
(Autoimmune & biliary diseases;
miscellaneous)
Chairpersons: A. Lleo De Nalda, Rozzano
F. Morisco, Naples
12.20-12.35 Identification of Twinfilin-1 as a key
regulator of cholangiocyte biological
response to injury: evidence for a possible
role of ageing in the progression of
cholangiopathies
L. Maroni, C. Pinto, D.M. Giordano,
S. Saccomanno, C. Rychlicki, L. Trozzi,
M.C. Albertini, F. Orlando, E. Melum,
J. Banales, A. Benedetti, G. Svegliati Baroni,
M. Marzioni - Ancona, Urbino, Falconara
(AN), Oslo (Norway), San Sebastian (Spain)
12.35-12.50 Metformin reduces cell migration and
down-regulates epithelial to mesenchymal
transition (EMT) by AMPK / FOXO3a
pathway
in
human
intrahepatic
cholangiocarcinoma (CCA)
S. Di Matteo, D. Costantini, L. Nevi, A. Lustri,
C. Napoletano, J. Faccioli, F. Giulitti, E. Manzi,
A.M. DeRose, M.C. Bragazzi, G. Grazi,
P.B. Berloco, F. Giuliante, V. Cardinale,
G. Carpino, D. Alvaro - Rome
12.50-13.05 Microgravity maintains stemness and
enhance glycolytic metabolism in human
hepatic and biliary tree stem/progenitor
cells
D. Costantini, V. Cardinale, L. Casadei,
G. Carpino, L. Nevi, S. Di Matteo, A.M. Lustri,
S. Safarikia, F. Melandro, P. Berloco,
C. Manetti, D. Alvaro - Rome
13.05-13.20 Epidemiology of primary biliary cholangitis
in Italy: evidences from a real world
database
M. Marzioni, C. Bassanelli, B. Marini,
C. Ripellino, D. Urbinati, D. Alvaro - Ancona,
Milan, Rome
13.20-13.35 Characterisation of the immune response in
patients with drug induced liver injury
C. Bergamo, G. Germani, D. Bizzaro,
C. Frasson, G. Basso, A. Ferrarese, A. Zanetto,
S. Shalaby, I. Bortoluzzi, M. Gambato, M.
Senzolo, F.P. Russo, P. Burra Padua
13.35-14.35 Lunch break and Posters view
C. Rosso, Turin
14.35-15.35 General Assembly III
15.35-15.50 Presentation of the AISF distinguished
service award to Prof. Alfredo Alberti
Introduced by: E.G. Giannini, Genoa
Presenter: P. Angeli, Padua
(Fibrosis, cirrhosis, and portal hypertension
clinical)
Chairpersons: P. Angeli, Padua
A. Marzano, Turin
15.50-16.05 In-hospital mortality and length of stay in
cirrhotic patients with sepsis treated with
non-selective beta-blockers
A. Facciorusso, R. Villani, F. Bellanti,
R. Bruno, G. Fioravanti, G. Vendemiale,
G. Serviddio - Foggia
AISF
16.05-16.20 Local prothrombotic state in portal venous
system in cirrhosis
S. Shalaby, P. Simioni, E. Campello,
S. Gavasso, A. Zanetto, F. D'Amico,
E. Gringeri, U. Cillo, M. Battistel, P. Burra,
M. Senzolo - Padua
16.20-16.35 In experimental ascitic cirrhosis reduction of
adrenergic function by means of α2A
adrenergic
receptor
agonists
has
considerable aquaretic effects
G. Sansoè,
M. Aragno, R. Mastrocola,
M. Ayoubi, M. Parola - Turin
16.35-16.50 Extracellular vesicles induce renal tubular
cells apoptosis, oxidative stress and
functional abnormalities in patients with an
acute decompensation of cirrhosis
A. Brocca, D. Medica, S. Piano, A. Romano,
A. Sticca, V. Cantaluppi, P. Angeli - Padua,
Turin, Novara
16.50-17.05 Non-invasive tools to ruling out large
varices: RESIST-HCV vs Baveno VI criteria in
a large cohort of patients with HCV cirrhosis
V. Calvaruso, I. Cacciola, A. Licata,
S. Madonia, R. Benigno, F. Bronte, S. Petta,
G. Malizia, G. Bertino, M. Distefano,
R. Volpes, A. Montineri, A. Digiacomo,
G. Alaimo, B. Cacopardo, A. Davì, L. Guarneri,
I. Scalisi, G. Mazzola, F. Cartabellotta,
V. Portelli, M. Russello, G. Squadrito,
G. Raimondo, A. Craxì, C. Cammà,
V. Di Marco on behalf of RESIST-HCV (Rete
Sicilia Selezione Terapia-HCV)
17.05-17.20 Assessment of Sepsis-3 criteria in patients
with cirrhosis and bacterial infections
S. Piano, G. Chies, M. Tonon, A. Romano,
E. Vettore, M. Stanco, C. Pilutti, A. Brocca,
S. Fasolato, P. Angeli - Padua
17.20-17.35 Young Investigators Awards
Presenters for the 2 best oral communications
Basic: C. Ferrari, Parma
Clinical: P. Caraceni, Bologna
Presenters for the 2 best posters
Basic: L. Maroni, Ancona
C. Rosso, Turin
Clinical: R. D’Ambrosio, Milan
17.35
Closure of the Annual Meeting
AISF
Poster Session
Thursday, February 23rd
N°1
N°2
N°3
N°4
N°5
N°6
N°7
N°8
Ang-2 polymorphisms in relation to outcome in
advanced HCC patients receiving sorafenib
G. Marisi, M. Scartozzi, L. Faloppi, M. Iavarone, F.G.
Foschi, G. Lauletta, M. Valgiusti, S. Cascinu, G.L.
Frassineti, G. Ercolani, A. Dino, A. Casadei Gardini Meldola (FC), Cagliari, Milan, Faenza (RA), Bari,
Modena, Forli
Impact of multidisciplinary team approach to liver
tumors: 5-years experience
S. Okolicsanyi, V. Pontecorvi, G. Bonato, A. Ciaccio,
R. Perego, F. Romano, F. Uggeri, D. Leni, F. Vacirca,
A. Gambini, A. Mariani, M. Ratti, M. Acquati, N.
Zucchini, G. Bovo, R. Corso, M. Strazzabosco - Milan,
Monza (MB), New Haven (USA)
In experimental liver cirrhosis impaired secretion
of renalase into blood may lead to organ damage
and sympathetic overactivity
G. Sansoè, M. Aragno, R. Mastrocola, M. Ayoubi, M.
Parola - Turin
A novel role for heparanase in the onset of liver
fibrosis
M.F. Secchi, M. Crescenzi, F.P. Russo, M. Onisto, A.
Floreani - Padua
Local renin-angiotensin system in the kidney of
ascitic cirrhosis: an innocent bystander or a major
protagonist?
G. Sansoè, M. Aragno, R. Mastrocola, M. Ayoubi, M.
Parola - Turin
Durable response in the markers of cholestasis
through 24 months of open-label extension with
obeticholic acid in italian patients with primary
biliary cholangitis
P. Andreone, A. Floreani, P. Invernizzi, G. Mazzella,
J. Owens-Grillo, E. Smoot Malecha, L. MacConell
Bologna, Padua, Milan, San Diego (USA), Milan
Impairment of coronary microvascular function in
patients with Primary Biliary Cholangitis
N. Cazzagon, C. Dal Lin, I. Franceschet, L. Perini, G.
Famoso, F. Tona, A. Floreani - Padua
CEUS LI-RADS are effective in predicting the risk
hepatocellular carcinoma of liver nodules
E. Terzi, L. De Bonis, S. Leoni, F. Benevento, A.
Granito, F. Tovoli, P. Pini, L. Bolondi, F. Piscaglia
Bologna
N°9
N°10
N°11
N°12
N°13
N°14
N°15
Platelet count, spleen length and platelet
count/spleen length ratio for the diagnosis of
oesophageal varices in patients with hepatic
cirrhosis. A systematic review and meta-analysis
A. Colli, M. Fraquelli, D. Prati, D. Conte, G. Casazza
Lecco, Milan
Clinical
presentation
and
outcomes
of
hepatocellular carcinoma in elderly patients
referred to a tertiary center: 5-years experience
S. Okolicsanyi, G. Bonato, V. Pontecorvi, A. Ciaccio,
M. Gemma, M. Strazzabosco - Milan, New Haven
(USA)
Ruling-in and ruling-out significant fibrosis and
cirrhosis using a shear wave measurement method
G. Ferraioli, L. Maiocchi, R. Lissandrin, C. Tinelli, A.
De Silvestri, C. Filice - Pavia
Liver stiffness fibrosis thresholds of Fibroscan
cannot be adopted by all new elastography
machines: a comparative study
V. Salvatore, L. Mulazzani, V. Cantisani, A. Colecchia,
R. Di Donato, C. Felicani, A. Ferrarini, N. Gamal, V.
Grasso, G. Marasco, E. Mazzotta, F. Ravaioli, G.
Ruggieri, I. Serio, J.F. Sitouok Nkamgho, C. Serra, D.
Festi, C. Schiavone, L. Bolondi, F. Piscaglia - Bologna,
Rome, Chieti
Autoimmune hepatitis in children and adults: a
single centre experience
L. Perini, E. Nicoletto, E. Salami, P. Gaio, C. Mangini,
N. Cazzagon, V. Baldo, M. Cananzi, A. Floreani
Padua
Effectiveness of HCV antiviral treatment in patients
with cirrhosis or advanced fibrosis and end-stage
kidney disease on dialysis
F.R. Ponziani, M. Siciliano, R. Lionetti, C. Pasquazzi,
L. Gianserra, L. Lambiase, G. D’Offizi, A. Gasbarrini,
M. Pompili - Rome
Validation of the Bolondi stratification for
intermediate stage hepatocellular carcinoma
(HCC). Clinical and therapeutical implications
A. Mega, M. De Giorgio, H. Zoller, A. Finkenstedt, M.
Felder, S. Fagiuoli, M. Haefner - Bozen, Bergamo,
Innsbruck (Austria)
AISF
N°16 Impact of direct-acting anti-HCV treatments before
liver transplant on virological and clinical
outcomes of HCV patients at one year after
surgery
S. Martini, M. Sacco, S. Strona, A. Ottobrelli, F.
Tandoi, S. Mirabella, D. Cocchis, M. Salizzoni, G.M.
Saracco, R. Romagnoli - Turin
N°17 Worsening of serum lipid profile after direct acting
antiviral treatment
S. Gitto, A.F.P. Cicero, E. Loggi, M. Giovannini, F.
Conti, E. Grandini, V. Guarneri, A. Scuteri, G. Vitale,
C. Cursaro, C. Borghi, P. Andreone - Bologna
N°18 The immunomodulatory activity of SerpinB3 an
protease-inhibitor in vivo and in vitro
A. Cappon, G. Villano, S. Quarta, A. Biasiolo, C.
Turato, M. Ruvoletto, S. Sutti, S. Bruzzi, E. Novo, E.
Morello, S. Cannito, E. Albano, M. Parola, P.
Pontisso - Padua, Novara, Turin
N°19 Hypoxia-inducible factor 2α drives the progression
of experimental non-alcoholic fatty liver disease by
stimulating hepatocyte production of histidine rich
glycoprotein
S. Sutti, E. Morello, S. Cannito, E. Novo, C. Bocca, B.
Foglia, S. Bruzzì, E. Bugianesi, E. Albano, M. Parola
Turin, Novara
N°20 TERT promoter and CTNNB1 gene mutations
represent cancer signatures specific for hepatitis B
and hepatitis C related hepatocellular carcinoma
F. Pezzuto, F. Izzo, L. Buonaguro, C. Annunziata, F.
Tatangelo, G. Botti, F.M. Buonaguro, M.L.
Tornesello - Naples
N°21 Minimal increases of alpha-fetoprotein strongly
predict
HCC
development
in
caucasian
compensated HBV cirrhotics treated by entecavir
or tenofovir: a 7-year longitudinal cohort study in
225 patients
A. Loglio, G. Grossi, M. Iavarone, M. Viganò, A.
Sangiovanni, M. Colombo, P. Lampertico - Milan,
Rozzano (MI)
N°22 MiR-122 targets SerpinB3 and is involved in
Sorafenib resistance in hepatocellular carcinoma
D. Pollutri, F. Fornari, C. Turato, G. Villano, S.
Quarta, M. Ruvoletto, L. Bolondi, L. Gramantieri, P.
Pontisso - Bologna, Padua
N°23 Genetic variations in PD-1 and STAT4 genes do not
predict off-treatment functional cure in IFN
treated genotype D, HBeAg-negative patients with
chronic hepatitis B
E. Galmozzi, F. Facchetti, G. Grossi, A. Loglio, P.
Lampertico - Milan
N°24 Validation of the Baveno VI criteria for screening
of esophageal varices in patients with metabolic
and alcohol related compensated advanced
chronic liver disease
N. Mezzina, M. Viganò, T. Giulia, S. Labanca, R.
Lombardi, V.L. Mainardi, A.L. Fracanzani, P.
Lampertico, M. Rumi, M. Primignani - Milan
N°25 Inherited prothrombotic risk factors in children
with extrahepatic portal vein obstruction (EHPVO).
A case-control study
M. Primignani, I. Martinelli, G. Tosetti, M. Cheli, P.
Bucciarelli, M. Colusso, D. Alberti - Milan, Bergamo,
Brescia
N°26 Increase in transporter MATE-1 expression induced
by obeticholic acid correlates with higher biliary
excretion of asymmetric dimethylarginine during
hepatic ischemia/reperfusion injury
L.G. Di Pasqua, C. Berardo, V. Siciliano, R. Viscusi, V.
Rizzo, L. Adorini, P. Richelmi, A. Ferrigno, M. Vairetti
Pavia, San Diego (USA)
N°27 Clinical effectiveness of enhanced surveillance in
"super-high risk" cirrhotics as evaluated in the
ITA.LI.CA database
M. D'Elia, G. Peserico, F. Pelizzaro, A. Meneghetti, A.
Imondi, E. Giannini, F. Trevisani, F. Farinati Padua,
Genoa, Bologna
N°28 Lobe-specific oxidative stress and matrix
metalloproteinase activation in two animal models
of non-alcoholic fatty liver disease (NAFLD)
V. Siciliano, L.G. Di Pasqua, C. Berardo, V. Rizzo, P.
Richelmi, S. Perlini, A. Ferrigno, G. Palladini, M.
Vairetti - Pavia
N°29 Vitamin D deficiency is an independent risk factor
and is predictor of infections in patients affected
by HCV-related liver cirrhosis
A.R. Buonomo, E. Zappulo, R. Scotto, B. Pinchera,
A.E. Maraolo, F. Borrelli, G. Di Filippo, G. Borgia, I.
Gentile - Naples
N°30 Direct acting antiviral (DAA) therapy of HCV,
effects on the cryoglobulinemic vasculitis: a multi
center open label study
E. Mauro, L. Quartuccio, M. Ghersetti, M. Lenzi, S.
Gitto, P. Andreone, P. Casarin, S. De Vita, G.
Pozzato, C. Mazzaro - Pordenone, Udine, Bologna,
Trieste, Aviano (PN)
N°31 Dynamic risk prediction in Primary Biliary
Cholangitis using the UK-PBC cohort
M. Carbone, A. Nardi, H.F. Ainsworth, M.A.
Heneghan, G.M. Hirschfield, D. Thorburn, A.
Bathgate, M. Aldersley, J.M. Neuberger, D.D.
Stocken, H.J. Cordell, G.J. Alexander, R.N. Sandford,
D.E.J. Jones, G.F. Mells - Cambridge (UK), Milan
AISF
N°32 Established cirrhosis at the time of diagnosis
predicts adverse outcome in autoimmune
hepatitis: a retrospective cohort study
A. Gerussi, N. Halliday, D. Roccarina, F. Saffioti, P.
Polly, M. Pinzani, A. Marshall, D. Thorburn - London
(UK), Udine, Messina
N°33 Cirrhosis
regression
does
not
prevent
hepatocellular carcinoma in patients with a
sustained virological response to IFN
R. D'Ambrosio, A. Aghemo, E. Degasperi, A.
Sangiovanni, M.G. Rumi, M. Fraquelli, R. Perbellini,
P. Bedossa, M. Colombo, P. Lampertico - Milan,
Clichy (France), Rozzano (MI)
N°34 Impact of von Willebrand factor and ADAMTS-13
on the pro-coagulant imbalance of patients with
cirrhosis
V. La Mura, A. Tripodi, N. Bitto, G. Tosetti, V.
Chantarangkul, L. Baronciani, C. Valsecchi, F.
Peyvandi, F. Salerno, P. Lampertico, M. Colombo,
M. Primignani - Milan
N°35 DAA-based regimens in HBsAg/anti-HCV positive
patients: the need to control HBV replication to
avoid HBV reactivation
M. Macera, M. Stanzione, V. Messina, G. D’Adamo,
V. Sangiovanni, L. Fontanella, S. De Pascalis, G.
Stornaiuolo, G. Piai, G.B. Gaeta, I. Gentile, N.
Coppola - Naples, Caserta, Nocera (SA)
N°36 Liver microRNA hsa-miR-125a-5p may exert an
oncosuppressor effect on HCC
L. Onorato, N. Coppola, G. de Stefano, M. Panella,
V. Iodice, C. Minichini, N. Mosca, L. Desiato, N.
Farella, M. Starace, G. Liorre, N. Potenza, E. Sagnelli,
A. Russo - Naples, Caserta
N°37 Prognostic role of vascular endothelial growth
factor and hypoxia inducible factor in HCC patients
after
conventional
and
deb-mediated
chemoembolization
A. Meneghetti, G. Peserico, F. Pelizzaro, C. Pozzan,
V. Iurilli, R. Vezzaro, R. Cardin, M. Piciocchi, D.
Paccagnella, F. Farinati - Padua
N°38 Absolute quantification of intrahepatic HBV
covalently-closed-circular DNA by droplet digital
PCR
G.P. Caviglia, M.L. Abate, A. Olivero, C. Rosso, A.
Ciancio, E. Bugianesi, G.M. Saracco, A. Smedile
Turin
N°39 Hepatocellular carcinoma and metabolic risk
factors in a main reference center in Italy
R.I. Kamal Jouness, C. Rosso, M. Marietti, G.P.
Caviglia, A. Nascè, D. Campion, A. Cantamessa, P.
Carucci, E. Bugianesi - Turin
N°40 Entecavir monotherapy improves renal function in
patients developing renal side effects during longterm Tenofovir treatment without compromising
virological response: a multicenter real-life study
in 103 patients
M. Viganò, G. Grossi, A. Loglio, M. Cappelletti, S.
Zaltron, F. Castelli, P. Andreone, V. Messina, R.
Ganga, N. Coppola, A. Marrone, M. Russello, A.
Marzano, G. Taliani, M. Fasano, S. Fagiuoli, E. Villa,
F. Bronte, T. Santantonio, G. Brancaccio, F.
Facchetti, P. Lampertico - Milan, Brescia, Bologna,
Caserta, Cagliari, Naples, Catania, Turin, Rome,
Triggiano (BA), Bergamo, Modena, Palermo, Foggia
N°41 Copper levels contribute together with the myc
oncogene to liver transformation
C. Porcu, L. Antonucci, B. Barbaro, C. Balsano
Rome
N°42 Screening of oesophagogastric varices in virusrelated compensated advanced chronic liver
disease: beyond the Baveno VI criteria
G. Tosetti, V. La Mura, A. Aghemo, P. Lampertico, R.
D’Ambrosio, M. Viganò, G. Grossi, M. Fraquelli, M.
Colombo, M. Primignani - Milan
N°43 Clinical outcomes with long-term Sorafenib
treatment: a multicenter, real-life study
R. Sacco, S. Parodi, T. Zolfino, C. Saitta, L. Marzi, N.
Simonetti, S. Attardo, M. Rossa, G. Bresci, G.
Cabibbo - Pisa, Cagliari, Messina, Modena, Palermo
N°44 DAAs treatment in HCV recurrence after Liver
Transplantation: clinical usefulness of non-invasive
methods
F. Ravaioli, M.R. Tamè, G. Marasco, L. Vizioli, M.C.
Morelli, A.D. Pinna, F. Conti, P. Andreone, A.
Colecchia, D. Festi and Research Center for the
Study of Hepatitis (CRS) - Bologna
N°45 Liver Stiffness and serum fibrosis biomarker
variations after DAAs treatment: predictive role in
HCC development in in cirrhotic patients
F. Ravaioli, G. Mazzella, P. Andreone, F. Conti, S.
Brillanti, F. Buonfiglioli, I. Serio, G. Verucchi, M.L.
Bacchi Reggiani, G. Marasco, A. Colecchia, D. Festi
and Research Center for the Study of Hepatitis (CRS)
Bologna
N°46 An elevated degree of genetic variability
characterizes Hepatitis Delta Antigen (HDAg) and
correlates with high levels of serum HDV-RNA:
implication for disease progression and design of
new pharmacological targets
L. Colagrossi, R. Salpini, R. Scutari, A. Battisti, L.
Piermatteo, A. Bertoli, C. Minichini, P. Trimoulet, H.
Fleury, E. Nebuloso, M. De Cristofaro, G. Cappiello,
A. Spanò, V. Malagnino, T. Mari, A. Barlattani, N.
Iapadre, M. Lichtner, C.M. Mastroianni, I. Lenci, C.
Pasquazzi, G.M. De Sanctis, A. Galeota Lanza, M.
Stanzione, G. Stornaiuolo, M. Marignani, L. Sarmati,
AISF
M. Andreoni, M. Angelico, C.F. Perno, N. Coppola, V.
Svicher - Rome, Naples, Bordeaux (France), L’Aquila
N°47 Spleen stiffness measurement: a useful prognostic
tool in HCV patients treated with DAAs regimens
F. Ravaioli, G. Marasco, M.L. Bacchi Reggiani, G.
Mazzella, F. Buonfiglioli, A. Porro, S. Brillanti, A.
Colecchia, D. Festi and Research Center for the
Study of Hepatitis (CRS) - Bologna
N°48 The role of Spleen Stiffness measurement as
predictor of HCC recurrence after curative
resection in cirrhotic patients
G. Marasco, A. Colecchia, A. Colli, G. Casazza, F.
Ravaioli, A. Cucchetti, M. Cescon, A.D. Pinna, D.
Festi - Bologna, Lecco, Milan
N°49 Impact of adrenal dysfunction on psoas muscle
thickness assessed by computed tomography in
patients with liver cirrhosis
G. Privitera, L. Spadaro, D. Russo, S. Marchisello, F.
Purrello - Catania
N°50 Validation of a simple scoring system to predict
Sorafenib effectiveness in patients with
hepatocellular carcinoma
R. Tortora, A. Casadei Gardini, G. Cordone, G.
Marisi, F.G. Foschi, M. Scartozzi, R. Granata, L.
Faloppi, S. Cascinu, N. Silvestris, O. Brunetti, V.O.
Palmieri, G. Ercoloani, G.G. Di Costanzo - Naples,
Meldola (FC), Faenza (RA), Cagliari, Modena, Bari,
Forlì
Poster Session
Friday, February 24th
N°1
N°2
N°3
N°4
Advanced BCLC hepatocellular carcinoma includes
a very heterogeneous patient population treatable
with different therapies and with different
prognosis
F. Garuti, E.G. Giannini, L. Bucci, M. Valente, B.
Lenzi, F. Trevisani on behalf of Italian Liver Cancer
(ITA.LI.CA) group - Bologna, Genova
A genic and epigenetic combination therapy for
liver cancer
L. Rinaldi, G. Franci, V. Folliero, L. Palomba, R.
Isticato, C. Zannella, R. di Francia, I. De Sio, G.
Morelli, S. Lastoria, L. Altucci, C. Pedone, A.
Ascione, L.E. Adinolfi, M. Galdiero - Naples
Risk factors of early emergent hospital
readmission and 6-month mortality in patients
with cirrhosis after a recovery from bacterial or
fungal infection
F. Morando, S. Piano, S. Rosi, M. Stanco, C. Pilutti, E.
Vettore, A. Romano, S. Fasolato, M. Tonon, A.
Brocca, A. Sticca, P. Angeli - Padua
Effectiveness of Percutaneous Ethanol Injection in
relation to hepatocellular carcinoma size: a single
centre
experience
G.G. Di Costanzo, R. Granata, M. SanduzziZamparelli, L. Falco, G. Cordone, R. Tortora - Naples
N°5
N°6
N°7
In HBeAg-negative chronic HBV infection, HBsAg
levels profoundly differ among HBV-genotypes and
can be affected by the extent of HBsAg variability:
can quantitative HBsAg truly reflect intra-hepatic
HBV reservoir?
R. Salpini, A. Battisti, O. Anastasiou, U. Gill, L.
Colagrossi, A. Bertoli, L. Fabeni, V. Fini, L.
Piermatteo, A. Iuvara, V. Malagnino, C. Cerva, M.
Lichtner, C. Mastroianni, G. De Sanctis, M. Paoloni,
M. Marignani, C. Pasquazzi, N. Iapadre, T. Mari, G.
Parruti, I. Vecchiet, L. Sarmati, M. Andreoni, M.
Angelico, S. Grelli, P. Kennedy, J. Verheyen, C.F.
Perno, V. Svicher - Rome, Essen (Germany), London
(UK), Avezzano (AQ), L’Aquila, Pescara, Chieti
Hepatocellular carcinoma recurrence rate in HCV
infected patients treated with direct antiviral
agents. A single center experience
R. Granata, G.G. Di Costanzo, M. Sanduzzi
Zamparelli, M. Guarino, G. Cordone, G. D’Adamo, R.
Tortora - Naples
Effects of treatment with Maraviroc a CCR5
inhibitor on a human hepatic stellate cell line
N. Coppola, A. Perna, A. Lucariello, S. Martini, M.
Macera, M.A. Carleo, G. Guerra, V. Esposito, A. De
Luca - Naples
AISF
N°8
N°9
N°10
N°11
N°12
N°13
N°14
Child-Pugh score predicts ribavirin overexposure in
cirrhotic patients treated with direct-acting
antiviral agents
V. Guardigni, L. Badia, M. Rinaldi, S. Ianniruberto, P.
Viale, G. Verucchi - Bologna
Serum markers for early diagnosis of HCC in HCV
cirrhotic patients with SVR to DAA treatment
A. Sangiovanni, R. D'Ambrosio, G. Lunghi, M.
Bruccoleri, E. Alimenti, M. Borghi, R. Perbellini, A.
Aghemo, M. Iavarone, M. Colombo, P. Lampertico
Milan, Rozzano (MI)
Eradication of HCV in patients awaiting liver
transplantation does not increase drop-out due to
HCC progression
S. Shalaby, A. Zanetto, A. Vitale, A. Ferrarese, I.
Bortoluzzi, M. Gambato, M. Senzolo, G. Germani, C.
Mescoli, A. Romano, E. Gringeri, G. Zanus, P.
Angeli, U. Cillo, P. Burra, F.P. Russo - Padua
FAK depletion/inhibition reduces the expression of
liver cancer stem cells markers
I. Romito, D. Gnani, S. Artuso, C. De Stefanis, N.
Panera, A. Crudele, C. Balsano, E. Carcarino, V.
Nobili, R. Rota, C. Leonetti, A. Alisi - Rome
In HCV infected patients with cirrhosis Squamous
Cell Carcinoma Antigen (SCCA)-IgM levels may
contribute to identify the individual risk of HCC
development after antiviral therapy
G. Ricco, D. Cavallone, P. Pontisso, G. Fassina, A.
Gallotta, P. Colombatto, F. Oliveri, V. Romagnoli, B.
Coco, A. Salvati, F. Bonino, M.R. Brunetto - Pisa,
Padua, Venice, Chianciano Terme (SI)
Validation of Liver Imaging Reporting and Data
System (LI-RADS) Version 2014
A. Pecorelli, R. Nani, F. Sala, D. Pinelli, M. De
Giorgio, G. Magini, M. Colledan, S. Fagiuoli, S. Sironi
Milan, Bergamo
Multiclass HCV resistance to interferon-free direct
acting antivirals regimens in real life failures
advocates for tailored second-line therapies
V.C. Di Maio, V. Cento, I. Lenci, M. Aragri, S.
Barbaliscia, S. Francioso, S. Paolucci, M. Melis, G.
Verucchi, C. Masetti, N. Coppola, C.F. Magni, V.
Micheli, T. Pollicino, T. Ruggiero, S. Landonio, A.
Mancon, M. Starace, F. De Leonardis, F. Santopaolo,
A. Bertoli, F.P. Antonucci, C. D’Ambrosio, V.
Calvaruso, M.C. Sorbo, F. Morisco, C. Pasquazzi, I.
Maida, A. Picciotto, A. Di Biagio, B. Bruzzone, L.
Sticchi, V. Ghisetti, R. Cozzolongo, D. Romagnoli, V.
Boccaccio, A. Grieco, J. Vecchiet, G. D’Ettorre, M.
Merli, G.B. Gaeta, A. Ciancio, L. Marinaro, E. Polilli,
P. Cacciatore, P. Andreone, G. Barbarini, R.
Gulminetti, S. Novati, V. Pace Palitti, P. Tarquini, M.
Puoti, V. Sangiovanni, G. De Stefano, A. Giorgini, M.
Paoloni, N. Caporaso, S. Babudieri, G. Gubertini, S.
Bruno, M. Andreoni, A. Pellicelli, G. Parruti, G.
N°15
N°16
N°17
N°18
N°19
Raimondo, F. Baldanti, G. Rizzardini, A. Craxì, M.
Angelico, C.F. Perno, F. Ceccherini-Silberstein on
behalf of HCV Virology Italian Resistance Network
Group (Vironet C) - Rome, Pavia, Sassari, Bologna,
Naples, Milan, Messina, Turin, Palermo, Genoa,
Castellana Grotte (BA), Modena, Rozzano (MI),
Chieti, Pescara, Teramo, Avezzano (AQ)
Liver stiffness and portal hypertension predict
failure to DAA treatment in a real-life cohort of
HCV-infected patients treated with recommended
regimens
C. Masetti, F. De Leonardis, P. Rossi, A. Bosa, D. Di
Paolo, M. Milana, F. Santopaolo, A. Pecchioli, S. Di
Nardi, S. Francioso, I. Lenci, L. Baiocchi, A. Brega,
T. Marianelli, F. Antenucci, M. Angelico - Rome
Laparoscopic ablation for HCC: proposal of a 6months mortality score for patient selection based
on more than 1000 procedures
A. Bertacco, A. Marchini, A. Vitale, C. Ungaro, F.
D'Amico, E. Gringeri, D. Neri, D. Bassi, G. Zanus, R.
Carandina, C. Aliberti, U. Cillo - Padua
Treatment with direct-acting antiviral agents is
associated with improvement of renal function in a
cohort
of HCV-infected patients with chronic
kidney disease
C. Masetti, F. De Leonardis, P. Rossi, A. Bosa, D. Di
Paolo, M. Milana, F. Santopaolo, A. Pecchioli, S. Di
Nardi, S. Francioso, I. Lenci, L. Baiocchi, A. Brega, F.
Antenucci, T. Marianelli, M. Angelico - Rome
Natural HCV resistance is common in Italy and
differently associated to genotypes
M.C. Sorbo, V. Cento, A. Bertoli, I. Lenci, E. Polilli, C.
Masetti, L. Gianserra, E. Teti, E. Biliotti, C.F. Magni,
M. Aragri, V. Micheli, M. Melis, L.A. Nicolini, S.
Marenco, V. Calvaruso, S. Paolucci, F Baldanti, F.
Morisco, M. Siciliano, V. Pace Palitti, P. Andreone,
B.Bruzzone, N. Coppola, T. Ruggiero, M. Lichtner, B.
Menzaghi, D. Romagnoli, N. Iapadre, V.C. Di Maio, F.
De Leonardis, M. Milana, P. Cacciatore, A Pieri, L.
Sarmati, S. Landonio, A. Gasbarrini, M. Puoti, A.
Craxì, V. Vullo, A. Pellicelli, S. Babudieri, G.
Rizzardini, G. Taliani, M. Andreoni, C. Pasquazzi, G.
Parruti, M. Angelico, C.F. Perno, F. CeccheriniSilberstein - Rome, Pescara, Milan, Sassari, Genoa,
Palermo, Pavia, Naples, Pescara, Bologna, Latina,
Varese, Baggiovara (MO), L'Aquila, Turin
HCV resistance test guided retreatments after
protease inhibitors failures can induce maximal
efficacy rate in real-life
V. Cento, S. Barbaliscia, I. Lenci, T. Ruggiero, C.
Masetti, C.F. Magni, V. Micheli, S. Paolucci, Y.
Troshina, E. Biliotti, M. Milana, M. Melis, E. Teti, L.
Lambiase, B. Menzaghi, L.A. Nicolini, S. Marenco,
V.C. Di Maio, M. Aragri, A. Pecchioli, A. Bertoli, F.P.
Antonucci, L. Sarmati, C. Sarrecchia, M. Macera, N.
AISF
N°20
N°21
N°22
N°23
N°24
Coppola, E. Danieli, D. Romagnoli, A. Pellicelli, S.
Bonora, S. Babudieri, A. Di Biagio, A. Picciotto, S.
Novati, M. Siciliano, V. Messina, E. Claar, F. Baldanti,
C. Pasquazzi, A. Ciancio, M. Puoti, V. Ghisetti, M.
Andreoni, G. Taliani, G. Rizzardini, M. Angelico, C.F.
Perno, F. Ceccherini-Silberstein Rome, Turin, Milan,
Pavia, Sassari, Varese, Genoa, Naples, Baggiovara
(MO), Caserta
Impact of Acute-on-Chronic Liver Failure (ACLF) on
response to treatment with terlipressin and
albumin in patients with type 1 hepatorenal
syndrome
S. Piano, H. Schmidt, X. Ariza, A. Amoros, A.
Romano, E. Solà, A. Gerbes, M. Bernardi, C.
Alessandria, J. Trebicka, T. Gustot, F. Nevens, V.
Arroyo, P. Gines, P. Angeli - Padua, Münster
(Germany), Barcelona (Spain), Munich (Germany),
Bologna, Turin, Bonn (Germany), Brussels (Belgium),
Leuven (Belgium)
Low viremic HBeAg negative HBsAg carriers:
clinical outcome and non invasive diagnostic
accuracy for chronic hepatitis B or inactive
infection by combinations of HBV markers
F. Oliveri, L. Surace, D. Cavallone, P. Colombatto, G.
Ricco, N. Salvati, B. Coco, V. Romagnoli, R. Gattai,
A. Salvati, F. Moriconi, Q. Yuan, F. Bonino, M.R.
Brunetto - Pisa, Xiamen (China), Chianciano Terme
(SI)
Thromboelastographic evaluation of hemostatic
balance in cirrhotic patients with infection
E. Nadal, P. Simioni, L. Spiezia, P. Angeli, S. Fasolato,
A. Zanetto, A. Ferrarese, S. Shalaby, G. Germani, F.P.
Russo, P. Burra, M. Senzolo - Padua
Ultrasound-guided
Percutaneous
Irreversible
Electroporation (IRE) of Hepatocellular Carcinoma
(HCC) not suitable for surgery or thermal ablation:
initial report on safety and efficacy from a western
center
A. Giorgio, P. Gatti, C. Coppola, A. Calvanese, F.
Amendola, B. Santoro, M.G. Merola, F. Merola, P.
Matteucci, V. Giorgio - Salerno, Rome
Transjugular intrahepatic portosystemic shunt is a
safe and effective approach in cirrhotic patients
with splanchnic vein thrombosis
A. Airoldi, S. De Nicola, G. Perricone, M. Vangeli, R.
Viganò, R. Vercelli, C. Migliorisi, M. Solcia, F.
Barbosa, F. Musca, A. De Gasperi, L.S. Belli, A.G.
Rampoldi - Milan
N°25 Decreased alpha-fetoprotein levels in HCV cirrhotic
patients after direct-acting antiviral agents
therapy. Does this indicate a reduced risk of
hepatocellular carcinoma?
F. De Leonardis, C. Masetti, P. Rossi, D. Di Paolo, A.
Bosa, M. Milana, F. Santopaolo, S. Cucchiarelli, A.
Pecchioli, S. Francioso, I. Lenci, A. Brega, T.
Marianelli, F. Antenucci, S. Di Nardi, L. Baiocchi, M.
Angelico - Rome
N°26 Bacterial infection is an uncommon occurrence in
cirrhotic patients undergoing endoscopic variceal
ligation
S. Maimone, G. Caccamo, R. Filomia, S. Sabatini,
M.S. Franzè, C. Saitta, K. Sitajolo, M.A. Aragona, F.
Saffioti, C. Pitrone, I. Cacciola, G. Squadrito, G.
Raimondo - Messina
N°27 Frailty index is a strong predictor of in-hospital
outcomes and mortality after discharge in cirrhotic
patients
G. Caccamo, G. Basile, S. Maimone, D. Vadalà, T.
Crea, M.S. Franzè, A. Sitibondo, R. Filomia, C. Saitta,
I. Cacciola, G. Squadrito, G. Raimondo - Messina
N°28 Efficacy of early empiric antibiotic treatment and
its impact on short-term mortality in cirrhotic
patients with subsequent identification of the
infecting bacteria
G. Caccamo, M.S. Franzè, R. Filomia, P. Mondello,
I.A. Paolucci, K. Sitajolo, M.A. Aragona, T. Lembo, C.
Saitta, I. Cacciola, G. Squadrito, G. Raimondo, S.
Maimone - Messina
N°29 Liver Stiffness Based Model (LSPS) predicts portal
hypertension (PH), esofageal varices (EV) and HCC
in caucasian patients with HBV-related cirrhisis
responsive to antiviral therapy
A. Tucci , W. Debernardi Venon, C. Chialà, M. Fadda,
G.M. Saracco, A. Marzano - Turin
N°30 HBV reactivation in pOBI is influenced by
detectable viremia at baseline rather than
duration of prophylaxis with lamivudine
F. Cavallo, P. Ghione, M. Battaglini, B. Botto, D.
Caracciolo, S. Ferrero, R. Passera, U. Vitolo, M.
Boccadoro, A. Marzano - Turin
N°31 Risk of Hepatocellular Carcinoma (HCC) Recurrence
in HCV Cirrhotic Patients treated with Direct Acting
Antivirals (DAAs)
G. Cabibbo, I. Cacciola, M.R. Cannavò, S. Madonia,
V. Calvaruso, S. Petta, M. Distefano, L. Larocca, T.
Prestileo, F. Tinè, A. Digiacomo, G. Bertino, L.
Giannitrapani, F. Benanti, A. Davì, R. Volpes, I.
Scalisi, C. Iacobello, G. Mazzola, F. Cartabellotta, L.
Guarneri, V. Portelli, A. Averna, M. Russello, G.
Scifo, G. Squadrito, G. Raimondo, A. Craxì , V. Di
Marco, C. Cammà on behalf of RESIST-HCV (Rete
AISF
N°32 Early occurrence of hepatocellular carcinoma (HCC)
in patients with HCV cirrhosis treated with directacting antivirals (DAAs)
V. Calvaruso, G. Cabibbo, I. Cacciola, S. Petta, S.
Madonia, A. Bellia, F. Tinè, M. Distefano, L.
Giannitrapani, T. Prestileo, G. Mazzola, A. Davì, L.
Larocca, A. Ardiri, A. Digiacomo, M. Gussio, L.
Guarneri, A. Magro, A. Averna, C. Iacobello, I. Scalisi,
F. Cartabellotta, F. Savalli, M. Russello,
G. Scifo, G. Squadrito, C. Cammà, G. Raimondo, A.
Craxì, V. Di Marco on behalf and RESIST-HCV (Rete
N°33 HLA-G is highly expressed by plasma cells
infiltrating hepatic tissue of patients affected by
autoimmune hepatitis
S. Onali, F. Figorilli, E. Sanna, C. Balestrieri, G. Serra,
M. Conti, F. Alba, M. Trucas, D. Fanni, G. Senes, A.
Mereu, G. Faa, C. Carcassi, R. Littera, L. Chessa
Cagliari
N°34 Survival and Recurrences after curative treatments
of HCV-related early Hepatocellular Carcinoma. A
meta-analysis of single arm studies
G. Cabibbo, S. Petta, M. Barbàra, G. Missale, R.
Virdone, E. Caturelli, F. Piscaglia, F. Morisco, A.
Colecchia, F. Farinati, E. Giannini, F. Trevisani, A.
Craxì, M. Colombo, C. Cammà on behalf of the
ITA.LI.CA study group - Palermo, Parma, Viterbo,
Bologna, Naples, Padua, Genoa, Milan
N°35 Are detectable sofosbuvir trough concentrations
predictive of virological failure during anti-HCV
treatment? Preliminary evidences from the KINETIC study
A. De Nicolò, L. Boglione, C. Carcieri, J. Cusato, S.
Mornese Pinna, F. Favata, A. Ariaudo, G. Di Perri, A.
D’Avolio - Turin
N°36 Prevalence and characteristics of resistance
associated substitutions in DAA-naive and DAAfailed HCV-3 patients in Italy
V.C. Di Maio, S. Barbaliscia, I. Lenci, E. Teti, F.P.
Antonucci, V. Cento, M. Aragri, S. Paolucci, B.
Bruzzone, N. Coppola, T. Ruggiero, T. Pollicino, E.
Polilli, C. Pasquazzi, V. Pace Palitti, C.F. Magni, V.
Micheli, A. Di Biagio, L. Sticchi, M. Melis, S.
Francioso, C. Masetti, L. Foroghi, C. Sarrecchia, L.
Baiocchi, S. Landonio, A. Bertoli, V. Calvaruso, F.
Morisco, I. Maida, S. Marenco, A. Leo, V. Ghisetti, A.
Ciancio, P. Sacchi, S. Novati, G. Brancaccio, A. Pieri,
M. Puoti, P. Toniutto, V. Vullo, A. Aghemo, G. Di
Perri, S. Babudieri, G. Rizzardini, S. Bruno, A.
Pellicelli, G. Taliani, G. Raimondo, F. Baldanti, G.B.
Gaeta, A. Craxì, G. Parruti, M. Andreoni, M.
Angelico, C.F. Perno, F. Ceccherini-Silberstein on
behalf of HCV Virology Italian Resistance Network
Group (Vironet C) - Rome, Pavia, Genoa, Naples,
N°37
N°38
N°39
N°40
N°41
Turin, Messina, Pescara, Milan, Sassari, Palermo,
Rozzano (MI), Udine
Evaluation of mild cognitive dysfunction by
montreal cognitive assessment test in patients
with chronic
HCV infection treated with
direct antiviral agents
S. Onali, D.G. Pacini, C. Balestrieri, F. Figorilli, G.
Serra, L. Chessa - Cagliari
Comparative antiviral efficacy with higher ALT
normalization of Tenofovir Alafenamide (TAF)
Versus Tenofovir Disoproxil Fumarate (TDF) in
HBeAg-negative, Genotype D Chronic Hepatitis B
G. Ricco, M. Buti, M. Omata, Y.J. Kim, B. Coco, D.
Samuel, J.F. Flaherty, L. Lin, A. Gaggar, E. Ceausu,
U.S. Akarca, M.J. Tong, H.L. Chan, M.R. Brunetto Pisa, Barcelona (Spain), Kōfu-shi (Japan), Seoul
(Korea), Villejuif (France), Foster City (USA),
Bucuresti (Romania), Izmir (Turkey), Pasadena
(USA), Hong Kong
Daclatasvir/Sofosbuvir and Ribavirin 800 mg flat
dose is highly efficacy and safe in genotype 3
compensated and decompensated cirrhotic
patients: the cleo experience
A. Pellicelli, V. Messina, P. Tarquini, V. Pace Palitti,
F. Ceccherini Silberstein, M. Pompili, R. Gulminetti,
G. Cerasari, C. D’Ambrosio, R. Villani, L. Fondacaro,
S. Dell’isola , S. Babudieri, V. Iovinella, F. Di Candilo,
F. Chiesara, V.C. Di Maio, F.R. Ponziani, R. Sacco, A.
Izzi, A. Moretti, V. Giannelli, C.F. Perno, G. Barbarini
for the CLEO Group - Rome, Caserta, Teramo,
Pescara, Pavia, Viterbo, Sassari, Naples, Perugia,
Pisa
Emerging players in liver fibrosis regression in a
chronic murine model of hepatic injury
M. Crescenzi, C. Frasson, D. Gabbia, S. De Martin,
M.T. Conconi, G. Basso, P. Burra, F.P. Russo - Padua
Portosystemic shunts in cirrhosis are associated to
more complications and deteriorated quality of
life. An international cohort study
M. Simón-Talero, D. Roccarina, A. Majumdar, E.A.
Tsochatzis, J. Martínez, C. Picón, A. Albillos, K.
Lampichler, D. Toth, T. Reiberger, A. Baiges, A.
Darnell, V. Hernandez-Gea, G. Low, J. G. Abraldes, P.
Tandon, E. Llop, M. Lopez, J.L. Calleja, M. Praktiknjo,
G. Kukuk, J. Trebicka, M. Maurer, A. Berzigotti, A.
Zipprich, C. Ripoll, M.
Triolo, V. La Mura, G.
Vangrinsven, W. Laleman, R. Garcia-Martinez, R.
Bañares, A. Dam, A. Krag, S. Augustin, J. Genescà
and the Baveno VI-SPSS group Barcelona (Spain),
London (UK), Alcalá (Spain), Madrid (Spain), Vienna
(Austria), Edmonton (Canada), Bonn (Germany),
Berne (Switzerland), Halle-Saale (Germany), Milan,
Leuven (Belgium), Odense (Denmark)
AISF
N°42 High rate of misclassification of fibrosis stage using
Transient elastography thresholds to prioritize HCV
patients for antiviral treatment
V. Calvaruso, F. Bronte, B. Magro, E. Conte, S. Petta,
D. Cabibi, A. Craxì, C. Cammà, V. Di Marco - Palermo
N°43 The prevalence of liver diseases due Hepatitis C
Virus (HCV) in Sicily: a population-based survey
F. Cartabellotta, V. Calvaruso, C. Paci, F. Magliozzo,
V. Milazzo, C. Crisafulli, C. Lo Curcio, M. Russello, A.
Digiacomo, L. Galvano, L. Spicola, V. Di Marco
RESIST-HCV (Rete Sicilia Selezione Terapia-HCV),
Società Italiana di Medicina Generale (SIMG) Sicilia
N°44 HCC onset and features among chronic hepatits B
patients treated with nucleos(t)ide analogues
M. Schranz, M. De Giorgio, G. Conte, L. Pasulo, G.
Magini, S. Fagiuoli - Bergamo
N°45 Effect of interferon free antiviral therapy on
glomerular and tubular kidney involvement in HCV
child-A cirrhosis
D. Palazzo, E. Biliotti, F. Tinti, A. Bachetoni, L.
Volpicelli, A. Cappoli, M.D. D’Alessandro, R. Labriola,
P. Perinelli, S. Grieco, M. Subic, I. Umbro, P. Rucci,
A.P. Mitterhofer, G. Taliani - Rome, Bologna
N°46 The old patient in DAA era: real life reports on
5925 patients from the LOMBARDY HCV NETWORK
L. Pasulo, A. Aghemo, S. Fargion, A. Spinetti, G.
Cologni, F. Maggiolo, G. Rizzardini, M. Puoti, R.
Bruno, L. Minoli, M. Zuin, C. Uberti, T. Quirino, A.
D'Arminio Monforte, A. Colli, M.G. Rumi, C. Iegri, S.
Fagiuoli, M. Colombo - Milan, Brescia, Bergamo,
Pavia, Busto Arsizio (VA), Lecco
N°47 Genotype 3 infection in DAA era: reports of a real
life NORTHERN ITALY NETWORK FOR VIRAL
HEPATITIS after 2 years by the start
L. Pasulo, A. Aghemo, T. Quirino, P. Viganò, P.
Bonfanti, E. Buscarini, M. Strazzabosco, M. Puoti, M.
Vinci, P. Perini, M. Colpani, M. Colombo, S. Fagiuoli Bergamo, Milan, Busto Arsizio (VA), Legnano (MI),
Lecco, Crema (CR), Monza (MB), Ponte San Pietro
(BG)
N°48 Pre-emptive post-liver transplant (LT) HCV
treatment with DAAS: proof of concept from a
pilot study
L. Pasulo, C. Mazzarelli, C. Iegri, L. De Carlis, R.
Viganò, F. Donato, G. Rossi, A. Zanetto, S. Shalaby,
S. Fagiuoli, L. Belli - Bergamo, Milan, Padua
N°49 Early Changes in non invasive assessment of liver
fibrosis in hepatitis C virus-infected patients
treated with DAAs: preliminary reports
C. Iegri, L. Pasulo, M. Colpani, L. Sangiovanni, G.
Rizzatti, M. Schranz, G. Magini, M. De Giorgio, M.G.
Lucà, G. Gaffuri, S. Fagiuoli - Bergamo
N°50 Treatment of chronic Hepatitis C in Lombardia: an
analysis on the safety and efficacy of DAA therapy
in 5457 patients
A. Aghemo, L. Pasulo, M. Puoti, S. Zaltron, F.
Maggiolo, G. Rizzardini, S. Fargion, R. Bruno, M.
Zuin, T. Quirino, M.G. Rumi, A. Pan, P. Grossi, A.
Rossini, A. Corbellini, S. Fagiuoli - Milan, Brescia,
Bergamo, Pavia, Busto Arsizio (VA), Cremona,
Varese, Vizzolo Predabissi (MI)
AISF
INFORMAZIONI GENERALI
Sede:
Aula Magna Università di Roma “Sapienza”
P.le A. Moro, 5
00185 ROMA
www.uniroma1.it/ateneo/dove-siamo
Provider E.C.M. (ID 1547):
A.I.S.F. - Associazione Italiana per lo Studio del Fegato
Via Alfredo Catalani, 39 - 00199 ROMA
Tel. e Fax: 06-86399303
E-mail: [email protected]
www.webaisf.org
Segreteria Organizzativa:
SPAZIO CONGRESSI S.r.l.
Via Alfredo Catalani, 39 - 00199 ROMA
Tel. e Fax: 06-86204308
E-mail: [email protected]
Modalità di partecipazione:
Socio A.I.S.F. (in regola con il versamento delle quote associative): partecipazione gratuita
Non Socio A.I.S.F.: € 260,00 (inclusa IVA 22%)
e comprende:
Partecipazione ai lavori congressuali
Kit congressuale
Coffee breaks
Colazioni di lavoro
Nuovi Soci A.I.S.F.
Per accedere in qualità di Socio A.I.S.F. all’Evento Formativo e, pertanto, per usufruire della quota agevolata, è necessario
iscriversi all’A.I.S.F. la cui modulistica è presente sul sito: www.webaisf.org o contattare direttamente la Segreteria A.I.S.F.
L’iscrizione all’A.I.S.F. dà diritto alla partecipazione gratuita alle Riunioni Istituzionali “Riunione Generale Annuale”, “Riunione
Monotematica” e “Special Conference”, all’abbonamento gratuito alla rivista Digestive and Liver Disease, all’utilizzo gratuito
dell’App di A.I.S.F. ed a ricevere qualsiasi informazione relativa all’attività dell’Associazione.
Modalità di pagamento (Non Socio A.I.S.F.):
tramite bonifico bancario intestato alla Segreteria Organizzativa “SPAZIO CONGRESSI S.r.l.” tratto sulla BANCA INTESA
SANPAOLO S.p.A. - Filiale di Roma 03 Montesacro n. 00453 - IBAN: IT 77 Q 03069 03202 100000031635.
N.B.: Le iscrizioni prive di compilazione e spedizione della Scheda di Pre-Iscrizione unitamente alla copia del pagamento non
saranno prese in considerazione e, pertanto, considerate nulle.
Cancellazione e rimborsi:
Le cancellazioni pervenute entro il 08 Febbraio 2017, tramite comunicazione scritta alla Segreteria Organizzativa, daranno diritto
ad un rimborso totale dell’importo versato, detratto l’importo di € 15,00 per spese amministrative.
Superata la data del 08 Febbraio 2017 non saranno riconosciuti rimborsi. I rimborsi saranno effettuati solo dopo il termine
dell’Evento.
E.C.M. - Educazione Continua in Medicina e Destinatari Attività Formativa
L’Evento Formativo ID 1547-178700 è accreditato per n. 350 partecipanti, per le seguenti categorie professionali: Biologo e
Medico Chirurgo specializzate per le seguenti discipline: Gastroenterologia; Malattie Infettive; Medicina Interna; Chirurgia
Generale; Microbiologia e Virologia; Medicina Generale (Medici Di Famiglia); con N° 3,3 Crediti.
Obiettivo Formativo E.C.M. - Educazione Continua in Medicina:
Epidemiologia - Prevenzione e Promozione della Salute con Acquisizione di Nozioni Tecnico-Professionali.
Procedure di attestazione della partecipazione e valutazione dell’apprendimento ai fini E.C.M. - Educazione Continua in
Medicina:
Ogni partecipante potrà conseguire i crediti assegnati all’Evento rispettando i seguenti requisiti:
compilazione dell’Autodichiarazione di apprendimento completa di Anagrafica partecipante;
partecipazione al 90% dell'intera attività formativa con verifica tramite “badge elettronico” in entrata e in uscita.
Il mancato rispetto dei suindicati requisiti non darà diritto ai crediti E.C.M., ma solamente all’attestato di partecipazione.
L’attestato E.C.M. verrà spedito a tutti i partecipanti che ne avranno diritto dopo il termine dell’Evento all’indirizzo di posta
elettronica riportato sul questionario.

PROGRAMMA.ANN.MEET.2017.rev.del 12_Feb.2017

Transcript

Documenti analoghi

A I S F

Clicca qui per scaricare il Programma dei lavori

Scarica Programma

L AN Z A F R AN CES CO F e rra ra , V ia B e lle tti n . 1 4 0372

“Genetically modified mouse models to study the development of the

Assistenza all`anziano e informatica

october 18, 2011 ifom-ieo campus, milan, italy

19/06/2010: Il Milan Club Seregno al torneo di calcetto di Alternativa

milestones